About UMBRELLA Labs
Academic research of orally-bioavailable, nonsteroidal SARMs and peptides has exploded in recent years, spurred by hundreds of promising preclinical studies that seek to address a wide variety of topics. Unfortunately, the pace and depth of this research is severely limited by the exorbitant prices charged by large chemical companies who have long enjoyed a virtual monopoly on the research market. Umbrella Labs seeks to increase and improve biochemical and molecular biology exploration by lowering research costs, thus removing the barrier for small laboratories to enter into the research space.
The progress of research into selective androgen receptor modulators (SARMs) which have anabolic effects on the muscle—but with limited or nominal adverse effects on prostate and cardiovascular system tissues—has been of considerable interest for the treatment of aging men with inadequate endogenous testosterone levels. Nonsteroidal SARMs differ from testosterone chiefly due to their inability to convert to active metabolites, such as E2 and DHT, while retaining the ability to act as agonists in bone and muscle, yet only partial agonists in sex organs. Additionally, the more favorable pharmacodynamics and AR specificity of nonsteroidal SARMs compared to exogenous testosterone enables more precise pharmacological interactions actions that serve specific indications for clinical use.
The inherent tissue selectivity of SARMs as gene expression modulators is due to isoform-specific conformational changes, modulation of surface topology, and discrete protein–protein interactions between AR and other nuclear receptors. Since isoform- and ligand-specific receptor conformation and protein complements differ in each tissue, this ultimately drives tissue-specific gene expression.
However, not all SARMs are being interrogated for muscle-associated phenotypes. For instance, SARMs that are prostate antagonists, but muscle agonists, are actively being studied in the context of prostate cancer and benign prostate hyperplasia. Other SARMs which have been shown to activate gonadotropin suppression but without prostate stimulation might find application for male contraception.
Despite the promise of various proteins (e.g., bone morphogenetic protein‐2 (BMP‐2) and platelet‐derived growth factor [PDGF]) as anabolic agents that increase bone formation, many of them are not optimal for therapeutic applications due to their long sequences; this translates into high manufacturing costs, limited supply, and susceptibility to enzymatic degradation as well as side effects outside the skeletal system. Thus, there is a need for inexpensive, novel, short anabolic agents that promote bone formation to effectively treat bone loss associated with aging.
There has been a rapid increase in the study of peptides as potential medications for many diseases. Peptides represent a class of compounds that bind with exquisite specificity to their in vivo targets, resulting in high potencies of action and moderately limited off‐target side effects. Unlike proteins, peptides are smaller in size, more available, and cheaper to manufacture by fully synthetic biochemical methods. The short length of peptides permits their use not only in systemic injections but also as pills or solutions taken orally or sublingually (under the tongue) for bone growth stimulation in clinical research.
UMBRELLA Labs is a USA SARMs supplier that only offers the highest purity, research grade Selective Androgen Receptor Modulators (SARMs) in liquid and powder form for sale.
Browse our store or choose from the list of SARMs for sale below to buy SARMs today.